Regeneron Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| REGN.VI | 9995.HK | ROIV | 4593.T | RPRX | 214450.KQ | |
|---|---|---|---|---|---|---|
| Market cap | 85.94B | 40.23B | 27.61B | 33.08B | 39.04B | 2.34T |
| P/E (TTM) | 21.3 | 6.1 | — | 235.6 | 44.2 | — |
| Forward P/E | — | 46.7 | -27.5 | -8.6 | 11.6 | — |
| Price/book | 2.8 | 3.8 | 6.5 | 3.8 | 4.5 | — |
| Dividend yield | 0.39% | — | — | — | 1.39% | 1.66% |
| 1-year change | +57.43% | −19.94% | +85.85% | −47.95% | +65.67% | −56.00% |
| Today | −2.68% | +1.49% | +6.08% | −3.54% | +1.75% | +0.67% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All REGN.VI news ›Regeneron: 3 Key Takeaways for Long-Term Investors
An early-stage liver disease therapy cut fat by 70% in just 12 weeks, signaling the genetics engine's potential to fuel growth beyond current blockbusters. On its third quarter of 2026 earnings call, held on Oct. 30, 2026, Regeneron (REGN…
Regeneron Overhauls Executive Pay With Long-Term Performance Plan
Regeneron ( (REGN) ) has shared an update. The most recent analyst rating on (REGN) stock is a Hold with a $737.00 price target. To see the full list of analyst forecasts on Regeneron stock, see the REGN Stock Forecast page. Spark’s Take…
Regeneron (REGN) Receives a Hold from RBC Capital
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades. RBC Capital analyst Brian Abrahams maintained a Hold rating on Regeneron on October 27 and set a price target of…
Regeneron Pharmaceuticals Crushes Q3 2026 Profit Estimates by 21.8%
Strong beat delivered. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported Q3 2026 non-GAAP diluted earnings of $20.07 per share, sailing past the $16.48... The post Regeneron Pharmaceuticals Crushes Q3 2026 Profit Estimates by 21.8%…
Sanofi and Regeneron Advance Dupixent Coformulation in Key Phase 1 Study
Regeneron Pharmaceuticals (REGN), Sanofi SA (SNY) announced an update on their ongoing clinical study. The trial evaluates a coformulated Dupixent plus berahyaluronidase alfa injection versus standard Dupixent alone. The goal is to see if…
Regeneron Pharmaceuticals Releases Q3 2026 Financial Results
Regeneron Pharmaceuticals, Inc. The post Regeneron Pharmaceuticals Releases Q3 2026 Financial Results first appeared on Alphastreet. AlphaStreet Newsdesk powered by AlphaStreet Intelligence Regeneron Pharmaceuticals, Inc. delivered a…
Regeneron Pharmaceuticals, Inc. announces Quarterly dividend, payable on December 03, 2026
Regeneron Pharmaceuticals, Inc. announced Quarterly dividend of USD 0.9400 per share payable on December 03, 2026, ex-date on November 20, 2026 and record date on November 20, 2026.... Regeneron Pharmaceuticals, Inc. announces Quarterly…
Regeneron Is Just Getting Started
Regeneron enters a new growth cycle after a strong Q3, with Dupixent, Eylea HD, and pipeline momentum boosting the outlook. Read this analysis on REGN here. - Regeneron delivered a standout Q3, with net sales up 36% year-over-year to $5.1…
Regeneron Surges 13.55%: Here’s What It Means for Your Health Care ETFs
Regeneron's blockbuster earnings sent its stock soaring, but the real story is how that move ripples through the health care ETFs sitting inside millions of retirement accounts, and whether fund holders are more exposed than they realize.…
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call October 30, 2026 8:30 AM EDT Ryan Crowe - Senior Vice President of Investor Relations & Strategic AnalysisLeonard Schleifer - Co-Founder, President, CEO & Co-ChairmanGeorge…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com58
- seekingalpha.com24
- tradingview.com17
- theglobeandmail.com15
- markets.businessinsider.com14
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.